Hope and Disappointment: Covalent Inhibitors to Overcome Drug Resistance in Non-Small Cell Lung Cancer

被引：76

作者：

Engel, Julian ^{[1
]}

Lategahn, Jonas ^{[1
]}

Rauh, Daniel ^{[1
]}

机构：

[1] TU Dortmund Univ, Fac Chem & Chem Biol, Otto Hahn Str 4a, D-44227 Dortmund, Germany

来源：

ACS MEDICINAL CHEMISTRY LETTERS | 2016年 / 7卷 / 01期

关键词：

EGFR; MUTATIONS; GEFITINIB; ERLOTINIB; AZD9291;

D O I：

10.1021/acsmedchemlett.5b00475

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

In the last five years, the detailed understanding of how to overcome T790M drug resistance in non-small cell lung cancer (NSCLC) has culminated in the development of a third-generation of covalent EGFR inhibitors with excellent clinical outcomes. However, the emergence of a newly discovered acquired drug resistance challenges the concept of small molecule targeted cancer therapy in NSCLC.

引用

页码：2 / 5

页数：4

共 12 条

[1] Irreversible Protein Kinase Inhibitors: Balancing the Benefits and Risks [J].

Barf, Tjeerd ;

Kaptein, Allard .

JOURNAL OF MEDICINAL CHEMISTRY, 2012, 55 (14) :6243-6262

[2] AZD9291 in EGFR Inhibitor-Resistant Non-Small-Cell Lung Cancer [J].

Jaenne, Pasi A. ;

Yang, James Chih-Hsin ;

Kim, Dong-Wan ;

Planchard, David ;

Ohe, Yuichiro ;

Ramalingam, Suresh S. ;

Ahn, Myung-Ju ;

Kim, Sang-We ;

Su, Wu-Chou ;

Horn, Leora ;

Haggstrom, Daniel ;

Felip, Enriqueta ;

Kim, Joo-Hang ;

Frewer, Paul ;

Cantarini, Mireille ;

Brown, Kathryn H. ;

Dickinson, Paul A. ;

Ghiorghiu, Serban ;

Ranson, Malcolm .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (18) :1689-1699

[3] BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models [J].

Li, D. ;

Ambrogio, L. ;

Shimamura, T. ;

Kubo, S. ;

Takahashi, M. ;

Chirieac, L. R. ;

Padera, R. F. ;

Shapiro, G. I. ;

Baum, A. ;

Himmelsbach, F. ;

Rettig, W. J. ;

Meyerson, M. ;

Solca, F. ;

Greulich, H. ;

Wong, K-K .

ONCOGENE, 2008, 27 (34) :4702-4711

[4] Structural insights into how irreversible inhibitors can overcome drug resistance in EGFR [J].

Michalczyk, Anja ;

Klueter, Sabine ;

Rode, Haridas B. ;

Simard, Jeffrey R. ;

Gruetter, Christian ;

Rabiller, Matthias ;

Rauh, Daniel .

BIOORGANIC & MEDICINAL CHEMISTRY, 2008, 16 (07) :3482-3488

[5] Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial [J].

Miller, Vincent A. ;

Hirsh, Vera ;

Cadranel, Jacques ;

Chen, Yuh-Min ;

Park, Keunchil ;

Kim, Sang-We ;

Zhou, Caicun ;

Su, Wu-Chou ;

Wang, Mengzhao ;

Sun, Yan ;

Heo, Dae Seog ;

Crino, Lucio ;

Tan, Eng-Huat ;

Chao, Tsu-Yi ;

Shahidi, Mehdi ;

Cong, Xiuyu Julie ;

Lorence, Robert M. ;

Yang, James Chih-Hsin .

LANCET ONCOLOGY, 2012, 13 (05) :528-538

[6] EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib [J].

Pao, W ;

Miller, V ;

Zakowski, M ;

Doherty, J ;

Politi, K ;

Sarkaria, I ;

Singh, B ;

Heelan, R ;

Rusch, V ;

Fulton, L ;

Mardis, E ;

Kupfer, D ;

Wilson, R ;

Kris, M ;

Varmus, H .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (36) :13306-13311

[7] Rociletinib in EGFR-Mutated Non-Small-Cell Lung Cancer [J].

Sequist, L. V. ;

Soria, J-C ;

Goldman, J. W. ;

Wakelee, H. A. ;

Gadgeel, S. M. ;

Varga, A. ;

Papadimitrakopoulou, V. ;

Solomon, B. J. ;

Oxnard, G. R. ;

Dziadziuszko, R. ;

Aisner, D. L. ;

Doebele, R. C. ;

Galasso, C. ;

Garon, E. B. ;

Heist, R. S. ;

Logan, J. ;

Neal, J. W. ;

Mendenhall, M. A. ;

Nichols, S. ;

Piotrowska, Z. ;

Wozniak, A. J. ;

Raponi, M. ;

Karlovich, C. A. ;

Jaw-Tsai, S. ;

Isaacson, J. ;

Despain, D. ;

Matheny, S. L. ;

Rolfe, L. ;

Allen, A. R. ;

Camidge, D. R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (18) :1700-1709

[8] Epidermal growth factor receptor mutations in lung cancer [J].

Sharma, Sreenath V. ;

Bell, Daphne W. ;

Settleman, Jeffrey ;

Haber, Daniel A. .

NATURE REVIEWS CANCER, 2007, 7 (03) :169-181

[9] Insulin-like growth factor 1 (IGF1R)/insulin receptor (INSR) inhibitory activity of rociletinib (CO-1686) and its metabolites in nonclinical models [J].

Simmons, Andrew D. ;

Jaw-Tsai, Sarah ;

Haringsma, Henry J. ;

Allen, Andrew ;

Harding, Thomas C. .

CANCER RESEARCH, 2015, 75

[10] Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M [J].

Thress, Kenneth S. ;

Paweletz, Cloud P. ;

Felip, Enriqueta ;

Cho, Byoung Chul ;

Stetsonl, Daniel ;

Dougherty, Brian ;

Lai, Zhongwu ;

Markovets, Aleksandra ;

Vivancos, Ana ;

Kuang, Yanan ;

Ercan, Dalia ;

Matthews, Sarah E. ;

Cantarini, Mireille ;

Barrett, J. Carl ;

Jaenne, Pasi A. ;

Oxnard, Geoffrey R. .

NATURE MEDICINE, 2015, 21 (06) :560-562

← 1 2 →